Adaptive Biotechnologies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-79.49	-159.49	-225.25	-200.19	-207.28	-146.23
Depreciation & Amortization	18.09	19.26	22.23	20.92	13.95	8.47
Asset Writedown & Restructuring Costs	-	7.21	25.43	-	-	-
Loss (Gain) From Sale of Investments	-3.68	-8.21	-9.18	0.74	7.23	0.77
Stock-Based Compensation	51.6	53.61	62.91	55.48	43.25	24.76
Other Operating Activities	5.22	9.87	13.73	10.65	6.93	3.34
Change in Accounts Receivable	-4	-3.74	2.03	-22.65	-7.36	2.61
Change in Inventory	2.39	5.37	-2.84	0.82	-5.2	-4.99
Change in Accounts Payable	3.76	0.67	-5.41	7.11	3.94	7.5
Change in Unearned Revenue	-42.09	-10.48	-29.29	-56.5	-57.73	-43.39
Change in Other Net Operating Assets	-12.33	-9.28	-10.68	-0.33	9.53	-2.52
Operating Cash Flow	-60.53	-95.21	-156.32	-183.95	-192.73	-149.68
Capital Expenditures	-2.4	-3.66	-10.7	-16.35	-61.75	-18.8
Investment in Securities	70.72	81.46	140.34	19.25	242.96	-98.24
Investing Cash Flow	68.32	77.79	129.65	2.91	181.21	-117.04
Issuance of Common Stock	8.87	0.24	2.25	7.89	26.72	293.91
Other Financing Activities	-	-	-	124.38	0.43	-0.32
Financing Cash Flow	8.87	0.24	2.25	132.27	27.15	293.59
Net Cash Flow	16.66	-17.18	-24.43	-48.78	15.63	26.86
Free Cash Flow	-62.94	-98.88	-167.02	-200.29	-254.47	-168.49
Free Cash Flow Margin	-24.90%	-55.25%	-98.09%	-108.09%	-164.87%	-171.26%
Free Cash Flow Per Share	-0.42	-0.67	-1.16	-1.41	-1.81	-1.28
Cash Interest Paid	10.26	8.86	8.99	0.49	-	-
Levered Free Cash Flow	1.29	-24.48	-81.95	-90.17	-139.1	-60.55
Unlevered Free Cash Flow	8.65	-17.24	-73.33	-87.53	-139.1	-60.55
Change in Working Capital	-52.26	-17.45	-46.18	-71.55	-56.82	-40.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.